The notices it replaced
- Reissues: PA-23-232 PHS 2023-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
- 2 steps back: PA-22-178 PHS 2022-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
- 3 steps back: PA-21-262 PHS 2021-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
- 4 steps back: PA-20-265 PHS 2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
- 5 steps back: PA-19-270 PHS 2019-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed
- 6 steps back: PA-18-575 PHS 2018-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
- 7 steps back: PA-17-303 PHS 2017-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 8 steps back: PA-16-303 PHS 2016-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 9 steps back: PA-15-270 PHS 2015-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 10 steps back: PA-14-072 PHS 2014-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42]
- 11 steps back: PA-13-235 Reissue PHS 2013-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 12 steps back: PA-13-089 PHS 2013-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 13 steps back: PA-12-089 PHS 2012-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 14 steps back: PA-11-097 PHS 2011-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 15 steps back: PA-10-051 PHS 2010-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 16 steps back: PA-09-081 PHS 2009-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
Replaced by PA-27-102.
Who won it before
2,214 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $775,782,307 in first-year total cost, median $295,384.
Most frequent study sections
- Special Emphasis Panel[ZRG1 SBIB-T (10)]101
- Special Emphasis Panel[ZRG1 OTC-T (10)]81
- Special Emphasis Panel[ZRG1 ETTN-G (12)]62
- Special Emphasis Panel[ZRG1 ETTN-M (11)]55
- Special Emphasis Panel[ZRG1 BCMB-G (10)]52
Most frequent institutions
- L2 DIAGNOSTICS, LLC20
- FOX CHASE CHEMICAL DIVERSITY CENTER, INC19
- MEDOSOME BIOTEC, LLC11
- MICROBIOTIX, INC11
- AQUALUNG THERAPEUTICS CORP.8
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Minimally Invasive Local Delivery of Cardiac Gene Therapy2R42HL149495-02 | LEVIT, REBECCA DIANEROAN, ESRA | CORAMI BIOTECH INC., TN | $1,293,419 | ZHL1 |
| 2025 | Gene Therapy to Treat Ethanol-induced Osteoporosis Associated with Aldehyde Dehydrogenase 2 Deficiency in Post-menopausal East Asian Women2R42AA028465-02A1 | CRYSTAL, RONALD G | ENYX THERAPEUTICS, LLC, NY | $1,253,597 | ZAA1 |
| 2025 | Mitigating Injurious Falls in Older Adults Through Non-Injurious Fall and Gait Analysis From Floor Vibrations2R42AG059475-04A1 | FRITZ, STACY LYNNE | ADVANCED SMART SYSTEMS/EVALUATION TECHNO, SC | $1,150,314 | ZRG1 |
| 2025 | Commercialization of Algorithmic Non-thermal Ablation Technology for the Treatment of Inoperable Tumors2R42CA275587-02A1 | FONG, JORDANSANO, MICHAEL BENJAMIN | GRADIENT MEDICAL, INC., NC | $1,150,000 | ZRG1 |
| 2025 | Improved Methods and Commercialization of a Multimodal Vibrating Sharp-Edge Spray Ionization Source2R42GM142379-02A1 · under PA-23-232 | VALENTINE, STEPHEN | INVIBRAGEN INC., WV | $1,147,352 | ZRG1 |
| 2025 | Engineered Glioblastoma-specific T cells using Immunostimulatory Photothermal Nanoparticles2R42CA287488-02 | FERNANDES, ROHANSWEENEY, ELIZABETH E | IMMUNOBLUE, LLC, MD | $1,135,290 | ZRG1 |
| 2025 | Title: Developing a novel drug for neurobehavioral deficits in FASD2R42AA029025-02 | TORII, MASAAKI | COGTHERA, LLC, MD | $1,077,312 | ZAA1 |
| 2025 | Non Magnetic MRI Conditional External Defibrillator with Reduced Skeletal Muscle Contraction2R42HL166051-02 | HALPERIN, HENRY R | CORAM TECHNOLOGIES, INC., MD | $1,051,193 | ZHL1 |
| 2025 | Precision MRI with Protein Contrast Agent for Noninvasive Detection of Lung Fibrosis2R42HL170898-02 | LIU, GANGYANG, JENNY J. | INLIGHTA BIOSCIENCES, LLC, GA | $1,026,874 | ZRG1 |
| 2025 | Mitigation of Ionizing Irradiation-Induced Intestinal Damage by Second-Generation Probiotic LR-IFN-β2R42AI157357-03A1 · under PA-23-232 | GREENBERGER, JOEL SROGERS, CLAUDE J. | CHROMOLOGIC, LLC, CA | $1,015,000 | ZRG1 |
| 2025 | Developing a Clinically Relevant Radiosensitizer for Temozolomide-resistant Gliomas2R42CA246902-02 | CHEN, THOMAS C.MINEA, RADU | NEONC TECHNOLOGIES, INC., CA | $1,007,612 | ZRG1 |
| 2025 | Diamond NMR spectrometer for microfluidic metabolite profiling2R42GM145129-02 | ACOSTA, VICTOR MARCELJARMOLA, ANDREJS | ODMR TECHNOLOGIES, INC., CA | $1,004,525 | ZRG1 |
| 2025 | Hepatoselective Dihydrozuinolizone (HS-DHQ) Molecules for Treatment and Prevention of Hepatitis A Virus (HAV) Infection2R42AI177204-03 | DU, YANMING | HARLINGENE LIFE SCIENCES LLC, PA | $1,000,000 | ZAI1 |
| 2025 | Novel strategy to block AAV neutralizing antibody activity2R42TR004338-02 | ASKEW, CHARLES HLI, CHENGWEN | NABGEN, INC., NC | $993,865 | ZTR1 |
| 2025 | Discovery of Bunyaviral Endonuclease Inhibitors for Anti Viral2R42AI165102-03 | AMARASINGHE, GAYA K.LIU, GAI | MICROBIOTIX, INC, MA | $977,449 | ZRG1 |
| 2025 | Novel Adipose Targeted Gene Therapy for Lipodystrophy2R42DK138551-02 | CAO, LEIHAWKINS, AL | ZVELT THERAPEUTICS INC., OH | $974,604 | ZRG1 |
| 2025 | Tacrolimus-eluting nerve guidance conduit for enhanced regeneration in critical-sized peripheral nerve injuries2R42NS112066-02 · under PA-23-232 | AGARWAL, JAYANT PRASADAZAPAGIC, AZURGALE, BRUCESANT, HIMANSHUSHEA, JILL E | MICROSURGICAL INNOVATIONS, INC., UT | $919,846 | ZRG1 |
| 2025 | Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's disease2R42DK138578-02 | SCHULTZ, KENNETH | TRETHERA CORPORATION, CA | $905,290 | ZDK1 |
| 2025 | Development of a radiation-activatable nanoparticle for lung cancer therapy2R42CA257584-02A1 | XIE, JIN | ATHNA BIOTECH, INC., GA | $901,390 | ZCA1 |
| 2025 | Targeting Myosin to Treat Polycystic Kidney Disease2R42DK136452-02A1 | FREEDMAN, BENJAMIN SOLOMON | PLUREXA LLC, WA | $839,264 | ZDK1 |
| 2025 | Development of synthetic heparin to protect liver graft from ischemia reperfusion injury during transplantation2R42CA285005-03 | ARNOLD, KATELYN | GLYCO DISCOVERIES, INC, NC | $775,669 | ZRG1 |
| 2025 | Manufacturing Process Intensification for Pluripotent Stem Cell-Derived Rare Red Cell Production1R41HL178144-01 · under PA-23-232 | CHOU, STELLA TTHOMAS, ROBERT JAMES | SAFI BIOTHERAPEUTICS INC, MA | $568,264 | ZRG1 |
| 2025 | Electromechanically monitored engineered heart tissue platform1R41HL180172-01 | GOOD, CAMERON | NEUROLUX, INC., IL | $525,824 | ZRG1 |
| 2025 | Commercialization of a phylogenetic cell separation method for downstream purification of nucleic acids2R42GM140530-02 · under PA-23-232 | MARCIANO, MICHAELMCPIKE, MARK PATRICK | SYRACUSE BIOLABS, INC., NY | $510,862 | ZRG1 |
| 2025 | Engineered Monothiol Thioredoxin for Treatment of Radiation Induced Lung Injury1R41HL180185-01A1 | HEIFETZ, PETER B | ORPRO THERAPEUTICS, INC., CA | $508,988 | ZHL1 |
| 2025 | Developing Brain Penetrable AAV Gene Therapy for Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD)1R41NS145933-01 | LEE, HING CHEONG HENRYROTENBERG, ALEXANDER | GALIBRA NEUROSCIENCE, INC., MA | $500,000 | ZNS1 |
| 2025 | Development and Validation of a Compliant Reversible Actuator and Detector Leveraging Electrophysiology for Organoids (Organoid-CRADLE)1R43MH143569-01 | GOOD, CAMERON | NEUROLUX, INC., IL | $499,781 | ZRG1 |
| 2025 | The development of an RT-qPCR Assay for early diagnosis of Alzheimer's Disease1R41AG097320-01 | BISHNOI, RAMCAO, CHUANHAI | MEGANANO DIAGNOSTICS INC., FL | $483,346 | ZAG1 |
| 2025 | Novel Technologies for Detection and Monitoring of Lung Disease1R41LM015295-01A1 | BHATT, SHIV KUMAR | SPIROMATICS, INC., DE | $471,544 | ZRG1 |
| 2025 | Development of PAR2 Pepducins for the Treatment of COPD1R41HL182486-01 | COVIC, LIDIJA | OASIS PHARMACEUTICALS, MA | $468,369 | ZHL1 |
| 2025 | Maximizing GlyTR pan-cancer immunotherapy by enhancing target density1R42CA302415-01A1 | DEMETRIOU, MICHAELZHOU, RAYMOND WENHOU | GLYTR THERAPEUTICS, INC., CA | $463,510 | ZCA1 |
| 2025 | Promoting tissue repair and functional recovery after spinal cord injury by targeting the microtubule regulatory protein Fidgetin-like 2.1R41NS137941-01A1 · under PA-23-232 | BAKER, LISA ANNBYRNES, KIMBERLY | MICROCURES, INC., CA | $458,154 | ZRG1 |
| 2025 | Development and Validation of Efficacy Biomarkers for QTE Therapy in Friedreich's Ataxia1R41NS143585-01 | CHANDRAN, VIJAYENDRAN | ANEKABIO LLC, FL | $454,437 | ZRG1 |
| 2025 | A precision functional neuroimaging platform to enable collection of highly-sampled data at home1R41MH139347-01A1 | BOWDEN, AUDREY KYNSELLARAHIMPOUR JOUNGHANI, ALI | WALNOT, INC., DE | $449,390 | ZRG1 |
| 2025 | High performance miniaturized microscopes for through skull cortex-wide imaging in freely behaving mice1R41OD039877-01 | KODANDARAMAIAH, SUHASA BSURINACH, DANIEL A | OBJECTIVE BIOTECHNOLOGY, INC., MN | $416,925 | ZRG1 |
| 2025 | Development of a DISE-inducing, short RNA therapeutic to treat ovarian cancer1R42CA291346-01A1 · under PA-23-232 | PETER, MARCUS E.SCHICKEL, ROBERT | NUAGO THERAPEUTICS INC, IL | $400,000 | ZRG1 |
| 2025 | Activating TFEB to enhance the efficacy of immunotherapy for triple negative breast cancer1R41CA298141-01 · under PA-23-232 | FAN, DAPING | PROMILEAD, LLC, SC | $400,000 | ZRG1 |
| 2025 | Nanoparticle formulation of Mediator kinase inhibitor for the treatment of peritoneal ovarian cancer1R41CA298223-01 · under PA-23-232 | CHEN, MENGQIANKARTHIKEYAN, MYTHREYE | SENEX BIOTECHNOLOGY, INC., SC | $400,000 | ZRG1 |
| 2025 | Optimized targeted radiotherapy of pancreatic cancer1R41CA284997-01A1 · under PA-23-232 | MUKHERJEE, PINKUZHOU, RU | ONCOTAB, INC, NC | $400,000 | ZRG1 |
| 2025 | Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment1R41CA298754-01 · under PA-23-232 | KANG, DONGKYUN | ARGOSMD, INC., CA | $400,000 | ZRG1 |
| 2025 | Targeting STAT3 with Novel Thiomorpholino Antisense Oligonucleotides for Cancer Therapy1R41CA287794-01A1 | LIU, XUEDONG | VESICLE THERAPEUTICS INC., CO | $400,000 | ZRG1 |
| 2025 | Development of a novel liver-specific positron emission tomography tracer1R41CA298176-01A1 | VAKILI, KHASHAYAR | ZEEST BIO INC, MA | $400,000 | ZRG1 |
| 2025 | Point of care diagnostic to improve access to gynecological screening in low-resource settings1R41CA298398-01A1 | CHRISTODOULIDES, NICOLAOS JOSEPH | ORALIVA, INC., FL | $400,000 | ZRG1 |
| 2025 | CHD1Li Targeted Combinations with Chemotherapy to Address Unmet Needs in Colorectal Cancer Treatment1R42CA306378-01 | ESQUER, HECTORGOODWIN, NEAL CLIFFORDLABARBERA, DANIEL V. | ONCONAUT THERAPEUTICS INC., CO | $400,000 | ZCA1 |
| 2025 | Passive cognitive assessment across the menopausal transition1R42AG094389-01 | AJILORE, OLUSOLA A.MAKI, PAULINE M | KEYWISE, INC., CA | $399,999 | ZRG1 |
| 2025 | Development of NEO212, A Novel Oral Drug for the Treatment of Acute Myeloid Leukemia1R41CA271879-01A1 · under PA-23-232 | CHEN, THOMAS C. | NEONC TECHNOLOGIES, INC., CA | $399,998 | ZRG1 |
| 2025 | Development of a potent and highly brain-penetrable antimitotic agent SEAK193 to treat breast cancer brain metastasis1R41CA310186-01 | LI, WEI | SEAK THERAPEUTICS, LLC, TN | $399,981 | ZRG1 |
| 2025 | Modified Thrombin Binding Aptamer Treatment of CRC Metastasis1R41CA302074-01A1 | GMEINER, WILLIAM H. | DEEP CREEK PHARMA, LLC, NC | $399,968 | ZCA1 |
| 2025 | Preclinical development of a tandem CART / HSC transplantation platform for hematologic malignancies1R41CA310331-01 | ELSER, JEREMY AGILL, SAAR | SHIP OF THESEUS, LLC, PA | $399,739 | ZRG1 |
| 2025 | Advancing cancer therapy: Developing antibody blockade targeting a novel immune checkpoint, LAIR1/CD3051R41CA298020-01 · under PA-23-232 | HUANG, JIANPING | IMMUNOGENIK, INC., FL | $398,997 | ZRG1 |
| 2025 | Enhance Cancer Therapeutics with 3-in-1 CAR T Cells1R41CA301978-01 | HUANG, JIANPING | IMMUNOGENIK, INC., FL | $398,997 | ZRG1 |
| 2025 | RegendoGEL for guided pulp and dentin regeneration1R41DE033326-01A1 · under PA-23-232 | BERTASSONI, LUIZ EDUARDOCRANE, MICHAELYELICK, PAMELA C | REGENDODENT, INC., MI | $398,785 | ZRG1 |
| 2025 | Development of Localized Triple-Negative Breast Cancer Immunotherapy1R41CA306678-01 | ZAHAROFF, DAVID | INTRA THERAPEUTICS, LLC, NC | $398,039 | ZCA1 |
| 2025 | Development and Feasibility Testing of PrivyPod - a modular bathroom to support aging in place1R41AG094413-01 | CHOVAN, CHRIS | VEST INC., PA | $397,982 | ZRG1 |
| 2025 | Novel technologies for cellular age profiling and validation1R41HG014741-01 | PERTSEMLIDIS, ALEXANDER | SYNTAXISBIO, INC., TX | $396,170 | ZHG1 |
| 2025 | Investigating Abbapolin PLK1 Polo Box Domain inhibitors as potential therapeutics for colorectal cancers1R41CA298584-01 · under PA-23-232 | MCINNES, CAMPBELL | PPI PHARMACEUTICALS, LLC, SC | $395,724 | ZRG1 |
| 2025 | Commercializing iDEP, an interactive and reproducible tool for analyzing RNA-Seq data1R41HG014101-01A1 | GE, XIJIN | RTUTOR, LLC, SD | $395,316 | ZRG1 |
| 2025 | A novel system for tracking arousal-related dynamics in freely moving animals1R41MH142265-01 | MCTAGGART, ELLORAPEGARD, NICOLAS CHRISTIAN RICHARDRODRIGUEZ-ROMAGUERA, JOSE | CAROLINA INSTRUMENTS, INC., NC | $394,708 | ZMH1 |
| 2025 | The development of humanized SEMA7A-antagonist mAbs for the therapeutic treatment of breast cancer1R41CA306717-01 | LYONS, TRACI | PEARL SCIENTIFIC LLC, CO | $392,695 | ZCA1 |
| 2025 | Development of an immune evasive stem cell line for Type 1 diabetes regenerative therapy1R41DK142395-01 · under PA-23-232 | SHEN, CHRISTOPHER | ALEUTIAN THERAPEUTICS, INC., CA | $372,067 | ZRG1 |
| 2025 | Investigating the safety and efficacy of pillararene sulfates as novel and effective reversal agents for both steroidal and non-steroidal neuromuscular blocking agents.1R41GM159487-01 | COTTEN, JOSEPH FSCHWARTZ, ANTHONY | REVERSAL THERAPEUTICS INC, MD | $368,367 | ZRG1 |
| 2025 | Design and optimization of TCR-T therapeutics by an advanced T cell receptor-antigen binding prediction platform1R41CA302099-01A1 | WANG, TAO | NIGHTSTAR BIOTECHNOLOGIES, INC, TX | $360,442 | ZRG1 |
| 2025 | High-Resolution Pseudouridine and m6A Sequencing Through Advanced Nanopore Adduct Analysis1R41GM157757-01 · under PA-23-232 | ERVIN, ERIC | ELECTRONIC BIOSCIENCES, INC., CA | $350,000 | ZRG1 |
| 2025 | Novel Extracorporeal Technology for Kidney Disease1R41DK139916-01A1 · under PA-23-232 | JOY, MELANIE S | KATHAROS, INC., CO | $350,000 | ZRG1 |
| 2025 | Tolerogenic Nanotherapy to Delay Type I Diabetes1R41DK142265-01 · under PA-23-232 | SCOTT, EVAN ALEXANDER | SNC THERAPEUTICS, INC., IL | $350,000 | ZRG1 |
| 2025 | Deep Reasoning AI Virtual Anatomical Technology & Augmented Reasoning Platform: Application to Craniomaxillofacial Reconstruction1R41DE034646-01 · under PA-23-232 | CHEN, DIMORRIS, JONATHAN M | DEEP REASONING AI INC, FL | $350,000 | ZRG1 |
| 2025 | Rapid and Ultra-Pure mRNA Production with Next-Generation RNA Polymerases1R41GM159477-01 | BHASKARAN, HARIFINKELSTEIN, ILYA J | CISTERNA BIOLOGICS, INC., CA | $350,000 | ZRG1 |
| 2025 | Novel imaging-based platform for cell quality and identity control1R42GM159493-01 | TERSKIKH, ALEXEY V | EPITUNE LLC, CA | $350,000 | ZRG1 |
| 2025 | Mnemonic-based digital platform for improved health literacy amount secondary students.1R41GM161136-01 | BLAND, TYLER | PANACEA INTERACTIVE LLC, ID | $350,000 | ZGM1 |
| 2025 | Fibroblast-derived Engineered Extracellular Vesicle (FieEV) Technology for Targeted Delivery of RNA Therapeutics to treat CMT1A Diseases1R41TR005758-01A1 | DUARTE SANMIGUEL, SILVIA M.PRICE, BRIAN | NEUCORE BIO, INC., OH | $350,000 | ZTR1 |
| 2025 | A Novel Multi-Lineage Human Intestinal Organoid Screening Platform for Drug Discovery and Preclinical Testing1R41TR005379-01A1 | CHILDS, CHARLIESPENCE, JASON | INTERO BIOSYSTEMS INC., CO | $349,952 | ZRG1 |
| 2025 | Novel AAV gene therapy for treating CNS neuropathy of MPS IIIC1R41NS143578-01 | FU, HAIYANMCCARTY, DOUGLAS M | NEUROGT, INC., NC | $349,909 | ZRG1 |
| 2025 | Spotting-free Nano-Oscillator Array for Quantification of Virion Displayed Membrane Protein Binding Kinetics1R42GM157918-01 · under PA-23-232 | LY, NGUYEN | BIOSENSING INSTRUMENT, INC., AZ | $349,566 | ZRG1 |
| 2025 | Scalable spatiotemporal-omics platform1R41GM156536-01A1 | LEE, JIHWANST-PIERRE, FRANCOIS | IMAGEN BIOWORKS INC., TX | $349,243 | ZGM1 |
| 2025 | Targeting ASK1 as a novel therapy to treat biliary atresia1R41DK143902-01 | MCDONNELL, NEILSHIVAKUMAR, PRANAVKUMAR | SEAL ROCK THERAPEUTICS, INC., WA | $346,910 | ZRG1 |
| 2025 | Redefining Dental Imaging: Low-Cost MRI with Relaxed Field Requirements1R41DE035423-01 | GROENKE, BETH RIDIYATULLIN, DJAUDAT | ORALMR LLC, MN | $341,970 | ZDE1 |
| 2025 | Soft-Landing of Size-Separated Macromolecules for Structural Analysis by Cryo-TEM1R41GM157850-01 · under PA-23-232 | PEREZ LORENZO, LUIS JAVIERRUOTOLO, BRANDON T | NANOENGINEERING CORPORATION, FL | $338,843 | ZRG1 |
| 2025 | An AI Enabled Training Tool for Complex Surgical Suturing Skills1R41EB038146-01 | XU, QIUYAN | BOSTON AI LLC, MA | $326,813 | ZEB1 |
| 2025 | Easy-to-Operate Endoscopic Automatic Gastroplasty Device That Mimics the Effect of Gastric Bypass/Bariatric Surgery for the Treatment of Diabetes and Obesity1R41DK143882-01 | BJERKEN, DAVID BERNARDLIN, EDWARD | INTAILOR BARIATRICS, LLC, GA | $325,408 | ZRG1 |
| 2025 | Maternal Health Navigator intervention to reduce disparities in severe maternal morbidity and mortality1R41HD117656-01 · under PA-23-232 | SURKAN, PAMELA JZACHARY, WAYNE W | STARSHIP HEALTH TECHNOLOGIES, PA | $321,341 | ZRG1 |
| 2025 | Translational Development of a Small Molecule for the Treatment of HBV Infection1R41AI195177-01 | GUO, HAITAOKAY, HEIDI A | JERICHO SCIENCES, LLC, VA | $320,863 | ZAI1 |
| 2025 | Advancing Native Mass Spectrometry Analysis with Easier, Faster and More Accurate Intact Mass Deconvolution for Proteins and Nucleic Acids1R41GM157865-01 · under PA-23-232 | FREITAS, MICHAEL A. | MASSMATRIX, INC., OH | $316,825 | ZRG1 |
| 2025 | Manufacturing and Analytical Validation of the Microfluidic Impedance Red Cell Assay (MIRCA) for Commercial Viability1R42HL182546-01 | FEDERICI, CHIARAGURKAN, UMUT A. | BIOCHIP LABS, INC., OH | $316,800 | ZHL1 |
| 2025 | Peptide YY triagonist weight loss drugs1R41DK145340-01 | BEINBORN, MARTINKUMAR, KRISHNA | VELUM, INC., MA | $315,342 | ZDK1 |
| 2025 | Chemoenzymatic methods and reagents to access affordable (iso)globo- and(neo)lacto-glycosphingolipids1R42GM163378-01 | LEE, L. ANDREW | INTEGRATED MICRO-CHROMATOGRAPHY SYSTEMS, INC., SC | $315,000 | ZRG1 |
| 2025 | Ultra-Sensitive, Rapid, Point-of-Use (POU) Mercury Sensor Enabled by Light-Pinpointed Enrichment1R41ES038039-01 | FAN, DONGLEI EMMA | MATERIALS NOVA LIMITED LIABILITY COMPANY, TX | $314,745 | ZES1 |
| 2025 | DelineateQSP: Accelerating Quantitative Systems Pharmacology Model Building and Repurposing1R41GM157892-01 · under PA-23-232 | IQBAL, JAWAD | DELINEATE INC, MA | $314,363 | ZRG1 |
| 2025 | Microfluidic device for detection of infectious prion proteins1R41AI186707-01A1 | OH, SANG-HYUN | PRIOGEN CORP, MN | $314,363 | ZRG1 |
| 2025 | Treating drug-resistant infections of burn wounds with an optimized antimicrobial peptide1R41AI191930-01 | GORR, SVEN-ULRIK | GAVIA BIO, LLC, MN | $314,363 | ZRG1 |
| 2025 | Full Gene Replacement for Hemophilia A Enabled by the StitchR Technology1R41HL180243-01 | GRAHAM, MARTIN | EMPRIME THERAPEUTICS INC, NY | $314,363 | ZRG1 |
| 2025 | Investigation of Novel IgY Technology for Fungal Targets in Alcohol-associated Hepatitis1R41AI191973-01 | CHANDRASEKHAR, SATISHCHANDRAN | PRODIGY BIOTECH, INC., PA | $314,363 | ZRG1 |
| 2025 | Combined Amikacin and Azithromycin in an Inhaled Formulation for the Treatment of NTM1R41AI195081-01 | WARNKEN, ZACHARY N | VIA THERAPEUTICS, LLC, TX | $314,363 | ZAI1 |
| 2025 | Microneedle-based mRNA Flu Vaccine for Transcutaneous Immunization1R41AI195038-01 | CUI, ZHENGRONGWARNKEN, ZACHARY N | VIA THERAPEUTICS, LLC, TX | $314,363 | ZAI1 |
| 2025 | AGT001 for Delayed Graft Function in Kidney Transplantation1R41DK142544-01A1 | BATLLE, DANIEL | ANGIOTENSIN THERAPEUTICS, INC., IL | $314,355 | ZDK1 |
| 2025 | Next Generation Stealth Lipid for the Delivery of mRNA1R41AI181391-01A1 · under PA-23-232 | CHILKOTI, ASHUTOSHHUCKNALL, ANGUS | GATEWAY BIO, INC., NC | $314,347 | ZRG1 |
| 2025 | Improving longitudinal mental health monitoring to generate personalized guides and timely referrals1R44MH140651-01A1 | ASTURIAS, GABRIELAKLEIN, ARNO | MIRESOURCE, INC., CA | $313,800 | ZMH1 |
| 2025 | Long-read sequencing-based diagnosis for complex genomic and DNA methylation changes1R41TR005388-01 · under PA-23-232 | CHEN, YI-WEN | D4Z4 MEDICINE, INC., MD | $313,372 | ZRG1 |
| 2025 | Accurate and actionable prediction of impending labor using deep learning on maternal physiological data1R41HD117576-01A1 | BASAVARAJ, CHINMAIERICKSON, ELISE N | AMAHEALTH LLC, AZ | $313,180 | ZRG1 |
| 2025 | Refinement of a novel at-home kit for contact dermatitis testing and diagnosis.1R41AR086685-01 | BRUCE, CHARLES J | ALLEVIATE SOLUTIONS INC, FL | $313,012 | ZAR1 |
| 2025 | Anti-sense oligonucleotide inhibitors of retinoic acid signaling and reversion of retinal remodeling for mitigating vision loss1R41EY036319-01A1 · under PA-23-232 | OCONNOR, STEVE | SHIFT PHARMACEUTICALS HOLDINGS, INC., MO | $312,239 | ZRG1 |
| 2025 | Vector mediated anti-vascular and anti-inflammatory therapy for AMD1R41EY036318-01A1 · under PA-23-232 | GILGER, BRIAN CHIRSCH, MATTHEW LOUIS | BEDROCK THERAPEUTICS, INC., NC | $310,952 | ZRG1 |
| 2025 | Controlling NETosis to Treat Diabetic Wounds.1R41DK142247-01 · under PA-23-232 | TAN, TAO | HTIC, INC., VA | $310,438 | ZRG1 |
| 2025 | Repurposing Pyrvinium as an Inhalation Therapy for Idiopathic Pulmonary Fibrosis1R41HL180136-01 | CARDELLI, JAMESDOWNEY, GREGORY PAUL | OLEOLIVE, INC., LA | $309,418 | ZRG1 |
| 2025 | Intraoperative Sensor to Comprehensively Measure Ligament Engagement During Knee Arthroplasty1R41AG093459-01 · under PA-23-232 | LIZALEK, LESLEY | TENSENSE LLC, WI | $308,927 | ZRG1 |
| 2025 | Improving accessibility, accuracy, and efficiency of auditory evoked response testing using a telehealth and artificial intelligence approach1R41DC022808-01 | DELGADO, RAFAEL E | INTELLIGENT HEARING SYSTEMS, FL | $308,712 | ZRG1 |
| 2025 | A novel Th17-enhancing adjuvant and conserved antigen for protection against viral/bacterial co-infection1R41AI188733-01A1 | AKERLEY, BRIAN | VISHENARY, LLC, DE | $308,669 | ZRG1 |
| 2025 | AAV-CRISPR engineering brown-like adipocytes targeting obesity and metabolic disorders1R41DK142538-01 · under PA-23-232 | LIU, YONGXING "JAMES" | UNITED BIOTHERAPEUTICS LLC, NJ | $307,508 | ZRG1 |
| 2025 | sxRNA-Select: Using RNAs for Positive Selection of Cell Lines, Enabling High-Yield Biotherapeutic Production1R41GM157947-01 · under PA-23-232 | TENENBAUM, SCOTT | SXRNA TECHNOLOGIES, INC., NY | $307,257 | ZRG1 |
| 2025 | Development of immune evasive strategies for allogeneic cell replacement therapies1R41AI191979-01 | SHEN, CHRISTOPHER | ALEUTIAN THERAPEUTICS, INC., CA | $307,091 | ZRG1 |
| 2025 | Restoring Self-Feeding with a Sensor Driven Robotic System1R41AG092186-01A1 | DEKAR, JONATHAN PAULERICKSON, ZACKORY | INDEPENDENT FEEDING DEVICE, LLC, FL | $306,872 | ZRG1 |
| 2025 | Sperm epigenetic diagnostic to inform couples time to pregnancy1R41HD118840-01A1 | PILSNER, J. RICHARD | RIPPLE BIOSCIENCES, LLC, MI | $306,872 | ZHD1 |
| 2025 | EMOTO: Development of a novel electromagnetic tracking technology for otology1R41DC023177-01 | NIKOU, CONSTANTINOS | IOTAMOTION, INC., MN | $306,872 | ZDC1 |
| 2025 | Synthetic circular supercoiled DNA: an alternative to plasmids for the production of lentiviral vectors for cell and gene therapies1R41GM161305-01 | BAI, HAIBO | CHESAPEAKE GENOMIC SYSTEMS LLC, MD | $306,872 | ZGM1 |
| 2025 | A Compliant Intramedullary Stem to Increase Longevity of Revision Total Knee Arthroplasty1R41AR086074-01 | PETERSON, BRANDON | FLEX ORTHOPAEDICS, INC., CA | $306,871 | ZRG1 |
| 2025 | Rapid Control and Assessment of Dissolved Gas Signals on Tissue Function andDisease.1R41GM161234-01 | ONEIL, TIMOTHY P | ENTOX SCIENCES, LLC, WA | $306,867 | ZGM1 |
| 2025 | AnchorChem LLC: Pioneering Solutions to Create a Stable Supply Chain of Cyanopeptides and Cyanotoxins to Address Global Health Threats1R41ES038414-01 | KODANKO, JEREMYSZLAG SILVA, REGINA | ANCHORCHEM LLC, MI | $306,842 | ZRG1 |
| 2025 | HLA Gene Editing in the Treatment of Rheumatoid Arthritis1R41AR086039-01 | FREED, BRIAN MFREED, RICHARD | RHEUMAGEN, INC., CO | $306,827 | ZRG1 |
| 2025 | Empowering Direct Care Workers with AI-Integrated Wearable Technology to Prevent Back Injuries1R41NR022031-01 | YOUNG, YUCHI | CARE4QOL LLC, NY | $306,817 | ZDK1 |
| 2025 | Developing a topical beta blocker formulation as a targeted therapeutic for infantile hemangioma1R41HL177866-01A1 | RENO, SETH | ARKAYLI BIOPHARMA, INC., MD | $306,804 | ZRG1 |
| 2025 | System for Malignant Lymph Node Identification1R41CA306716-01 | HAO, JIANGWANG, JING | DAIGNOSTX L.L.C., TX | $306,798 | ZCA1 |
| 2025 | Inhibitors of ENPP1 for the treatment of hepatocellular carcinoma1R41CA302163-01 | HO, WON JINSENGUPTA, DEEPA | RIBOSCIENCE, LLC, CA | $306,739 | ZRG1 |
| 2025 | Topical nitrite reverses nitroglycerin tolerance.1R41GM164306-01A1 | LIU, TAIMING | NANOS, INC., CA | $306,728 | ZHL1 |
| 2025 | Approaches to enable large scale heparin bio-manufacturing1R41HL177991-01 · under PA-23-232 | BALAGURUNATHAN, KUBERANCAPILA, ISHAN | BIOPARIN, LLC, UT | $306,656 | ZRG1 |
| 2025 | Vascular Regeneration with Reprogrammed Endothelial Cells1R41HL178334-01A1 | YOON, YOUNG-SUP | KARIS BIO USA, INC., GA | $306,607 | ZRG1 |
| 2025 | AI-enabled occult bleeding detection and monitoring1R41EB038858-01 | SADLEIR, ROSALIND J | EIT USA, INC., AZ | $306,508 | ZRG1 |
| 2025 | Bioinformatics pipeline for personalized diagnostics of transplant rejection1R41AI189162-01 · under PA-23-232 | BARSKI, ARTEM | DATIRIUM, LLC, OH | $306,500 | ZRG1 |
| 2025 | Developing allogeneic iNKT cell adoptive therapy to improve outcomes for HSCT indications1R41AI192061-01 | LE TONQUEZE, OLIVIER | MINK THERAPEUTICS INC, NY | $306,500 | ZRG1 |
| 2025 | MAGNETIC (MRI-Assisted Guidance via NeuroInterventional Targeted Imaging Catheters)1R41EB037527-01 | HETTS, STEVEN WILLIAM | DOGPATCH MEDICAL LLC, CA | $306,463 | ZRG1 |
| 2025 | Arsenic Removal from the Body Through Mechanism-Guided Gut Microbiome Modulation1R41ES038048-01 | LU, KUNROGERS, JOHN | LUXBIOME INC, NC | $306,374 | ZES1 |
| 2025 | Development of a high performance reduced cost OCT Otoscope1R41DC022812-01 | APPLEGATE, BRIAN E. | AO TECHNOLOGIES, LLC, CA | $306,311 | ZRG1 |
| 2025 | Development of a gene edited platform to enable human allogeneic cell replacement therapy1R41AI192172-01 | SHEN, CHRISTOPHER | ALEUTIAN THERAPEUTICS, INC., CA | $305,855 | ZRG1 |
| 2025 | Novel light source development for robust multi-MHz retinal OCT1R43EY038160-01 | JOO, JONGYOON | BLUEBIRD PHOTONICS, INC, MA | $305,853 | ZEY1 |
| 2025 | Leveraging the Highly Active Metabolite of Pioglitazone as a Scaffold for a Novel Non-Immunosuppressive Therapy for Childhood Nephrotic Syndrome.1R41DK146563-01 | REICHENBERGER, PATRICK | CYPRESS BIOPHARMA, INC., NC | $305,786 | ZRG1 |
| 2025 | Rapid and economical system for preparation of PFAS samples to lower the Method Detection Limit1R41ES038047-01 | ALBURTY, DAVID SWANG, ZHUO MICHAEL | INNOVAPREP, LLC, MO | $305,754 | ZES1 |
| 2025 | Cell type-specific gene therapy approach for TOMT-linked congenital hearing loss1R41DC022471-01 · under PA-23-232 | CUNNINGHAM, CHRISTOPHER LTZOUNOPOULOS, THANOS | ECHOGENESIS THERAPEUTICS INC, PA | $305,628 | ZRG1 |
| 2025 | Phonocath - An endovascular medical device to objectively evaluate Pulsatile Tinnitus1R41DC022504-01 · under PA-23-232 | AMANS, MATTHEW | VDF INDUSTRIES INC, CA | $305,197 | ZRG1 |
| 2025 | Advancing Extracellular Vesicle Therapy for Brain Cancer1R41CA302019-01 | STEINDLER, DENNIS A. | ROUND TABLE RESEARCH, INC., NC | $305,031 | ZRG1 |
| 2025 | Engineered Memory T cells as a Platform to Treat Enzymopathies1R41AI184248-01A1 · under PA-23-232 | SHIRKEY-SON, NICOLE J. | KOMMODO HOLDINGS CORP., MN | $304,838 | ZRG1 |
| 2025 | Preclinical Development of LCTG-001, a Human Secretory IgA Replacement Therapy for CVID Patients1R42AI188865-01 · under PA-23-232 | MANE, VIRAJ PRAMOD | LACTIGA US INC., NJ | $304,629 | ZRG1 |
| 2025 | Intramuscular Administration of AAV Vectors Encoding soluble PD-L1 for Rheumatoid Arthritis Treatment1R41AR086050-01A1 | LI, CHENGWENSUN, JUNJIANG | BEDROCK THERAPEUTICS, INC., NC | $304,502 | ZAR1 |
| 2025 | Cardiovascular risk prediction from AI analysis of coronary calcifications1R41HL180169-01 | HOORI, AMMARLEE, JUHWAN | PULSEIMAGING.AI, LLC, OH | $304,415 | ZRG1 |
| 2025 | Development of sIgA from human milk as a therapeutic for Inflammatory bowel disease1R41DK143877-01 | MANE, VIRAJ PRAMODSAVIDGE, TOR C. | LACTIGA US INC., NJ | $303,427 | ZRG1 |
| 2025 | Novel Stealth Lipid for use in HIV MPER Vaccine1R41AI195239-01 | HUCKNALL, ANGUS | GATEWAY BIO, INC., NC | $303,173 | ZAI1 |
| 2025 | Use a humanized monoclonal antibody as an emergency prophylactic and therapeutictreatment against human Q fever1R41AI188656-01 · under PA-23-232 | ZHANG, GUOQUAN | ZENVAX, LLC, TX | $301,674 | ZRG1 |
| 2025 | CARDIAC CASCADE: Cardiomyopathy and Arrhythmia Risk Dissemination through Innovative Family Sharing1R41HG014454-01 | SHAH, LISA LSNIR, MORAN | NEST GENOMICS, CA | $301,161 | ZRG1 |
| 2025 | Antibody Detection for Diagnosis of Acute Leptospirosis1R41AI188742-01A1 | DEVILLERS, CARLA ELLEN | LUNA BIOSCIENCE, INC., CT | $300,435 | ZRG1 |
| 2025 | Bispecific antibody targeting IgE-producing B cells for treating allergic diseases1R41AI188995-01 · under PA-23-232 | MA, ZHENGYU | CELLERGY PHARMA, DE | $300,000 | ZRG1 |
| 2025 | Development and optimization of a nitric oxide releasing microparticle formulation for the topical treatment of chronic rhinosinusitis1R41AI188793-01A1 | ABUZEID, WALEED MDRAGANSKI, ANDREW R | ZYLO THERAPEUTICS, INC., SC | $300,000 | ZRG1 |
| 2025 | Therapeutic nucleic acid vaccine for chronic hepatitis B in HIV/HBV co-infected individuals1R41AI195068-01 | BAGLEY, KENNETH CFULLER, DEBORAH H. | ORLANCE, INC., WA | $300,000 | ZAI1 |
| 2025 | Broad-spectrum, multivalent platform for pan-influenza vaccine1R41AI195180-01 | BUCHHOLZ, DAVID WILLIAM | VIVA VIRAL VACCINES, INC., NY | $299,968 | ZAI1 |
| 2025 | PfAg, a multivalent peptide vaccine against malaria1R41AI195230-01 | CHUANG, YU-MIN | L2 DIAGNOSTICS, LLC, CT | $299,954 | ZAI1 |
| 2025 | Novel Benzyl-Piperidine antifungal agents to treat intractable Mucorales infections1R41AI195240-01 | OPPERMAN, TIMOTHY J. | MICROBIOTIX, INC, MA | $299,946 | ZAI1 |
| 2025 | ND Enabling Studies for CMT-101, a Novel Gene Therapy for Glycogen Storage Disease 1b1R42DK141304-01A1 · under PA-23-232 | HAWKINS, ALLEE, YOUNGMOK | COMETA THERAPEUTICS INC, MD | $299,648 | ZRG1 |
| 2025 | A vaccine targeting mosquito metabolic pathways to eradicate malaria1R41AI195232-01 | CHUANG, YU-MIN | L2 DIAGNOSTICS, LLC, CT | $299,644 | ZAI1 |
| 2025 | Use of Apatinib-nanosponge conjugate to reduce post-radiation induced oral cavity and salivary fibrosis.1R41DE034312-01A1 | GAN, GREGORY NSIELECKI-DZURDZ, THAIS | DELTAMED LLC, MO | $298,942 | ZRG1 |
| 2025 | Development of nitroreductase-activated inhibitors to treat mycobacterial infections1R41AI194849-01 | VRBANAC, JOHN JAMES | TARN BIOSCIENCES, INC., MI | $298,829 | ZAI1 |
| 2025 | Epigenetic editor therapeutics1R41GM157863-01 · under PA-23-232 | FEDULOV, ALEXEY V | EPIGENTER, LLC, RI | $298,530 | ZRG1 |
| 2025 | Zinc nanocrystals from zinc tetraammine fluoride for caries arrest and remineralization1R41DE034627-01 · under PA-23-232 | LI, XINSAXENA, DEEPAK | PERIOMICS CARE, LLC, NY | $297,711 | ZRG1 |
| 2025 | Automated Microfluidics: Advancing Cell Culturing through Non-Sacrificial Analysis and Heterogeneous Microenvironments1R41GM154567-01A1 · under PA-23-232 | VORONOV, ROMAN S | ALTVIVO, INC., OK | $295,038 | ZRG1 |
| 2025 | Non Invasive Urine Output Monitor1R41EB036929-01A1 | BROWN, KATHERINE GENGLER | THORMED INNOVATION LLC, TX | $294,886 | ZEB1 |
| 2025 | High Signal-to-Noise Ratio Miniature Microphones for Hearing Assistive Devices1R41DC022811-01A1 | HALL, NEAL ALLEN | SILICON AUDIO RF CIRCULATOR, LLC, TX | $292,694 | ZDC1 |
| 2025 | Validation of APT101 for the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) in an Aging Murine Model1R41AG090138-01A1 | KNIPE, RACHEL SWILLETTE, ROBERT N | ARTIAM BIO INC., NC | $292,279 | ZRG1 |
| 2025 | HNK analog identification and characterization as an approach to non-opioid analgesics1R41NS145804-01 | TOLL, LAWRENCE RWAINER, IRVING | SPIRIFY PHARMA INC, FL | $290,784 | ZNS1 |
| 2025 | Novel approaches to humanized skeletal muscle in pig1R41AR086049-01A1 | GARRY, MARY G | NORTHSTAR GENOMICS, LLC, MN | $286,415 | ZAR1 |
| 2025 | Targeting eNAMPT-TLR4 signaling with the novel ALT-100 mAb to slow IPF progression1R41HL180035-01 | MIELE, STANLEY | AQUALUNG THERAPEUTICS CORP., FL | $284,699 | ZRG1 |
| 2025 | A viral vector-based vaccine to induce humoral and cellular immune protection against Powassan virus in a tick transmission model1R41AI188982-01A1 | MARIN LOPEZ, ALEJANDRO | L2 DIAGNOSTICS, LLC, CT | $281,786 | ZRG1 |
| 2025 | Novel peptide therapeutics to treat cystic fibrosis-related diabetes1R42DK145320-01 | SCHOTZINGER, ROBERT | ELDEC PHARMACEUTICALS, INC., NC | $280,122 | ZDK1 |
| 2025 | Bioengineering strategies for exogenic organ production1R41HL174447-01A1 · under PA-23-232 | GARRY, DANIEL J. | NORTHSTAR GENOMICS, LLC, MN | $279,750 | ZRG1 |
| 2025 | A whole-cell inactivated vaccine for improved protection against tuberculosis1R41AI186746-01A1 | ARTINGER, MICHAELDUTT, TARU S. | SOLARIS VACCINES, INC., CO | $269,874 | ZRG1 |
| 2025 | Quantum Sensing Integrated with Ultrasound for Precise Drug Screening1R41GM159474-01 | XU, SHOUJUN | UFORCE BIOTECHNOLOGY, LLC, TX | $267,323 | ZRG1 |
| 2025 | A Hydrogen Sulfide Delivery Technology for Organ Preservation Therapy1R43DK143762-01 | SHEKARRIZ, REZA | EXHALIX, LLC, NM | $248,492 | ZRG1 |
| 2025 | Targeted Localization and Optimized Surgical Resection for Lung Cancer1R41CA306611-01 | JAGADEESAN, JAYENDER | NAVIGATION SCIENCES, INC., MA | $225,229 | ZCA1 |
| 2024 | Development of negative allosteric modulators of the mu-opioid receptor for the management of opioid use disorder2R42DA056254-02 · under PA-23-232 | TRAYNOR, JOHN R. | ELEVEN THERAPEUTICS CORP, CA | $1,567,215 | ZRG1 |
| 2024 | A Robust Platform for Design and Development of Therapeutic Peptides for Metabolic Syndrome2R42DK131842-02 · under PA-23-232 | BEINBORN, MARTINKUMAR, KRISHNA | VELUM, INC., MA | $1,135,509 | ZRG1 |
| 2024 | An automated device for quantifying DNA damage2R44ES030274-02 · under PA-23-232 | COOKE, MARCUS STANLEYROSS, CHRISTOPHER | ENGINEERING RESOURCES GROUP, INC., FL | $1,047,828 | ZRG1 |
| 2024 | Development of a Peptide-Drug Conjugate for Topically Treating the Viral Skin Disease Molluscum Contagiosum2R42AI162385-03 · under PA-22-178 | RICCIARDI, ROBERT PAUL | FOX CHASE CHEMICAL DIVERSITY CENTER, INC, PA | $1,039,551 | ZRG1 |
| 2024 | A New Small-Molecule Kinase Inhibitor for Airway Disease2R42HL149523-02 · under PA-22-178 | BROSCHAT, KAY O | NUPEAK THERAPEUTICS, INC., MO | $1,018,383 | ZRG1 |
| 2024 | Establishing the market-readiness of an in vivo technology for assessing drug toxicity-induced tissue damage2R42GM140538-02 · under PA-23-232 | JOHNSON, STEVEN EDWARD | DURAMETRIX LLC, WI | $1,011,661 | ZRG1 |
| 2024 | Prevention of corneal transplant rejection using AAV-BDRK-401 therapy2R42EY031625-02 · under PA-22-178 | GILGER, BRIAN CHIRSCH, MATTHEW LOUIS | BEDROCK THERAPEUTICS, INC., NC | $975,387 | ZRG1 |
| 2024 | A New Anti-inflammatory Therapy for Ischemic Stroke2R42HL156322-02A1 · under PA-22-178 | LIANG, BRUCE | CORNOVUS PHARMACEUTICALS, INC., CT | $934,548 | ZRG1 |
| 2024 | Development of an integrated smartphone-nanosensor platform for onsite biomonitoring of exposure to pesticides2R42ES032388-02A1 · under PA-22-178 | WANG, JUN | NANODIAGNOSTIC TECHNOLOGY, LLC, NC | $915,031 | ZRG1 |
| 2024 | An accurate, affordable, and transferable assay for minimally invasive detection of esophageal squamous cell carcinoma (ESCC) in Africa and the United States2R42CA261376-02A1 · under PA-23-232 | LAUN, SARAH | CAPSULOMICS, LLC, MD | $885,000 | ZRG1 |
| 2024 | A Novel Non-Invasive Method of Dysphagia Detection in Preterm Infants: Bottle Finalization & Validation2R42HD104305-02 · under PA-23-232 | MCGRATTAN, KATLYN ELIZABETH | NUBORN MEDICAL, INC., MN | $859,275 | ZRG1 |
| 2024 | Automated microfluidic device for blood analysis in neonates2R42HD100251-02 · under PA-22-178 | GONZALEZ-SUAREZ, ALAN M | SERSENSE, INC., MN | $780,138 | ZRG1 |
| 2024 | Detection of extracellular vesicles in urine for diagnosis of preeclampsia2R42HD096993-02A1 · under PA-23-232 | STYBAYEVA, GULNAZ | SERSENSE, INC., MN | $780,138 | ZRG1 |
| 2024 | Clinical performance testing of neuropacs in Parkinsonism diagnosis2R42NS132614-02 · under PA-23-232 | BARMPOUTIS, ANGELOS | AUTOMATED IMAGING DIAGNOSTICS, LLC, FL | $736,624 | ZRG1 |
| 2024 | Development of a Novel AAV9 Gene Replacement Therapy for Neurofibromatosis Type 21R41NS135883-01 · under PA-22-178 | HENWOOD, NICOLENAEIMI KARAROUDI, MEISAM | MERLIN THERAPEUTICS INC, PA | $699,559 | ZRG1 |
| 2024 | Development of a Novel Aspiration Pump for Neurointerventional Procedures1R41NS134425-01A1 · under PA-23-232 | HANSER, MANNINGSTARKE, ROBERT MICHAEL | VON MEDICAL, INC, FL | $693,385 | ZRG1 |
| 2024 | STTR Phase II - Development of a visual-to-tactile conversion system for automating the tactile graphic generation process2R42EY031628-02A1 · under PA-22-178 | PALANI, HARI PRASATH | UNAR LABS, LLC, ME | $674,598 | ZRG1 |
| 2024 | Non-catalytic FAK inhibitors as novel therapeutics for lung fibrosis2R42HL162392-02 · under PA-23-232 | KNOX, KENNETH SMARLOWE, TIMOTHY A | FAKNOSTICS, LLC, AZ | $673,796 | ZRG1 |
| 2024 | Anatomic Imaging Derived 4D Hemodynamics using Deep Learning1R42HL174259-01A1 · under PA-23-232 | ALLEN, BRADLEY DAVID | THIRD COAST DYNAMICS, INC., IL | $656,751 | ZRG1 |
| 2024 | A Novel Xenon Delivery Platform for Cerebroprotection During Stroke2R42NS098918-04 · under PA-23-232 | BOOHER, KEITHHUANG, SHAOLING | ZYMO RESEARCH CORPORATION, CA | $631,721 | ZRG1 |
| 2024 | BREATH: Breakthrough Research in Electromyography for the Assessment of Sleep-disordered BreaTHing1R42HL176325-01 · under PA-23-232 | KOOLA, JEJO DAVIDMANDEVILLE, ROSS | POWELL MANSFIELD, INC., CA | $615,621 | ZRG1 |
| 2024 | Development of highly parallelized interferometric near-infrared spectroscopy for the real-time non-invasive measurement of cerebral blood flow1R41NS137832-01 · under PA-23-232 | KHOLIQOV, OYBEK | NEURALENZ, INC, NY | $498,995 | ZRG1 |
| 2024 | Novel brain-penetrant drugs for translation-targeting therapeutics of Alzheimer’s disease1R41AG085859-01 · under PA-22-178 | CHEN, XIAN | TRANSCHROMIX, LLC., NC | $497,218 | ZRG1 |
| 2024 | Lumbo-venous CSF Shunt for Treatment of Communicating Hydrocephalus.1R41NS135749-01A1 · under PA-23-232 | BRINJIKJI, WALEED | CONWAY MEDICAL LLC, MN | $492,983 | ZRG1 |
| 2024 | Dual-function Carbon Modified-Silicon Microelectrodes for Biomolecule Detection with Fast Scan Cyclic Voltammetry and Electrophysiology Recording and Stimulation1R41MH139088-01 · under PA-23-232 | ZESTOS, ALEXANDROS GEORGE | SPIKE NEURO LLC, MI | $491,579 | ZRG1 |
| 2024 | CD4-LINK: Improving access to HIV care in underserves areas with a home-based, mail-in CD4 count test1R41MH138179-01 · under PA-23-232 | FAHLBERG, MARISSAVACCARI, MONICA | SPOTTED TECH LLC, LA | $449,093 | ZRG1 |
| 2024 | Single telomere length analysis using DNA array and FISH: a low-cost and accurate test for telomere-associated diseases1R41AG085701-01 · under PA-22-178 | WANG, YINGZHENG, YUN-LING | TELOHEALTHDX LLC, MD | $448,961 | ZRG1 |
| 2024 | Flexible, scalable, and generalizable photogrammetric head modeling for high-density diffuse optical tomography1R41MH138258-01 · under PA-23-232 | TROBAUGH, JASON WAYNE | ESPERIMAGE LLC, MO | $446,490 | ZRG1 |
Showing the 200 most recent of 2,214 awards.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.